IEHP UM Subcommittee Approved Authorization Guidelines
Deflux Injectable Gel for Vesicoureteral Reflux (VUR) in Children

Policy:
On January 26, 2006, the IEHP Utilization Management Subcommittee accepted Deflux Injectable Gel Treatment for Vesicoureteral Reflux in Children as non-investigational with choice of material left to the surgeon’s discretion. Requests should be approved when meeting criteria for medical necessity.

Effective Date: January 26, 2006
Review Annually: November 9, 2016
Revised:

Bibliography:
1. ECRI Hotline Response

Disclaimer
IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP’s determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.